[Health economic evaluation of a 23 value pneumococcal polysaccharide vaccination pilot programme among elderly chronic obstructive pulmonary disease patients in China].

Qiu, Y P; Zhao, K; Li, X; Shi, L W; Guo, W D; Qi, X R; Sui, B Y; Zhou, R M

Qiu, Y P; Zhao, K; Li, X; Shi, L W; Guo, W D; Qi, X R; Sui, B Y; Zhou, R M.

Affiliation

Qiu YP; National Health Development Research Center, Beijing 100191, China.

Zhonghua Yu Fang Yi Xue Za Zhi ; 50(12): 1074-1078, 2016 Dec 06.

Article in Zh | MEDLINE | ID: mdl-28057111

Subject(s)

Cost-Benefit Analysis/methods; Immunization Programs/economics; Immunization/economics; Pneumococcal Vaccines/economics; Program Evaluation; Pulmonary Disease, Chronic Obstructive/complications; Vaccination/economics; Aged; China/epidemiology; Health Care Costs; Hospitalization; Humans; Pilot Projects; Quality of Life; Quality-Adjusted Life Years

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Program Evaluation / Immunization / Vaccination / Cost-Benefit Analysis / Immunization Programs / Pneumococcal Vaccines / Pulmonary Disease, Chronic Obstructive Type of study: Evaluation_studies / Guideline / Health_economic_evaluation Limits: Aged / Humans Country/Region as subject: Asia Language: Zh Journal: Zhonghua Yu Fang Yi Xue Za Zhi Year: 2016 Type: Article Affiliation country: China

Fulltext

XML

PubMed Links

Search on Google